Navega Therapeutics key facts
- Developer of gene therapies designed to treat chronic pain and tackle the opioid epidemic.
- It has raised $2.4M across 1 recorded rounds; the latest was Seed Round ($1.3M) in Jan 2026.
- Notable investors include Creative Destruction Lab, National Institutes of Health, University of California, CONNECT (San Diego), Good Ventures — 13 tracked in total.
- Status: Privately Held (backing).
Who backs Navega Therapeutics
13+Membership and data by Private Market View
- ·The complete investor list: 13 names
- ·Watch Navega Therapeutics: the Monday email on marks, rounds and moves
Navega Therapeutics funding rounds
1 roundsHow much has Navega Therapeutics raised?
Navega Therapeutics has raised $2.4 million in total; 1 of its rounds is on record. The largest on record was a $1.3 million seed round in Jan 2026.
Navega Therapeutics investors
13 investors are on record for Navega Therapeutics, including Creative Destruction Lab, National Institutes of Health, University of California and CONNECT (San Diego). The seed round in Jan 2026 drew 8 investors.
About Navega Therapeutics
Developer of gene therapies designed to treat chronic pain and tackle the opioid epidemic. The company's therapies target pain that is non-addictive, particular, and long-lasting, enabling healthcare practitioners to offer alternative treatments for chronic pain and reduce the amount of pain felt in one particular location.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Employees
- 7
- Website
- navegatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Navega Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.